Intest Res Search

CLOSE


‘Intestinal Research’ (Intest Res) is the joint official publication of the Asian Organization for Crohn's and Colitis (AOCC), Chinese Society of IBD (CSIBD), Japanese Society for IBD (JSIBD), Korean Association for the Study of Intestinal Diseases (KASID), Taiwan Society of IBD (TSIBD) and Colitis Crohn's Foundation (India) (CCF, india).
The aim of the Journal is to provide broad and in-depth analysis of intestinal diseases, especially inflammatory bowel disease, which shows increasing tendency and significance.As a Journal specialized in clinical and translational research in gastroenterology, it encompasses multiple aspects of diseases originated from the small and large intestines.

Statement

January 31, 2023


Use of device-assisted enteroscopy in small bowel disease: an expert consensus statement by the Korean Association for the Study of Intestinal Diseases
Han Hee Lee, Jin Su Kim, Hyeon Jeong Goong, et al.
Intest Res. 2023;21(1):3-19.

Review

January 31, 2023


Korean Guidelines for Postpolypectomy Colonoscopic Surveillance: 2022 revised edition
Su Young Kim, Min Seob Kwak, Soon Man Yoon, et al.
Intest Res. 2023;21(1):20-42.

Review

October 18, 2022


Korean clinical practice guidelines on biologics for moderate to severe Crohn’s disease
Seong-Joon Koh, Sung Noh Hong, Soo-Kyung Park, et al.
Intest Res. 2023;21(1):43-60.

Review

May 31, 2022


Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis
Soo-Young Na, Chang Hwan Choi, Eun Mi Song, et al.
Intest Res. 2023;21(1):61-87.

Original Article

March 11, 2022


Incidence rates for hospitalized infections, herpes zoster, and malignancies in patients with ulcerative colitis in Japan: an administrative health claims database analysis
Katsuyoshi Matsuoka, Kanae Togo, Noritoshi Yoshii, et al.
Intest Res. 2023;21(1):88-99.

Original Article

November 14, 2022


Improvement of ulcerative colitis control by searching and restricting of inflammatory trigger factors in daily clinical practice
Kun-Yu Tsai, Jeng-Fu You, Tzong-Yun Tsai, et al.
Intest Res. 2023;21(1):100-109.

Original Article

March 11, 2022


Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial
Toshifumi Hibi, Satoshi Motoya, Tadakazu Hisamatsu, et al.
Intest Res. 2023;21(1):110-125.

Original Article

July 22, 2022


Characteristics and usefulness of transabdominal ultrasonography in immune-mediated colitis
Kensuke Sakurai, Takehiko Katsurada, Mutsumi Nishida, et al.
Intest Res. 2023;21(1):126-136.

Original Article

July 12, 2022


Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study
Kyunghwan Oh, Hee Seung Hong, Nam Seok Ham, et al.
Intest Res. 2023;21(1):137-147.

Original Article

June 14, 2022


Compositional changes in fecal microbiota associated with clinical phenotypes and prognosis in Korean patients with inflammatory bowel disease
Seung Yong Shin, Young Kim, Won-Seok Kim, et al.
Intest Res. 2023;21(1):148-160.

Intestinal tuberculosis or Crohn’s disease: a review of the diagnostic models designed to differentiate between these two gastrointestinal diseases
Julajak Limsrivilai, Nonthalee Pausawasdi
Intest Res. 2021;19(1):21-32.

Review

Epub April 22, 2020

Use of thiopurines in inflammatory bowel disease: an update
Arshdeep Singh, Ramit Mahajan, Saurabh Kedia, et al.
Intest Res. 2022;20(1):11-30.

Review

Epub April 15, 2021

Colitis and Crohn’s Foundation (India): a first nationwide inflammatory bowel disease registry
Ajit Sood, Kirandeep Kaur, Ramit Mahajan, et al.
Intest Res. 2021;19(2):206-216.

Original Article

Epub July 13, 2020

Long-term outcomes of infliximab in a real-world multicenter cohort of patients with acute severe ulcerative colitis
Shin Ju Oh, Ga Young Shin, Hosim Soh, et al.
Intest Res. 2021;19(3):323-331.

Original Article

Epub August 18, 2020

Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study
Choon Jin Ooi, Ida Normiha Hilmi, Hyo-Jong Kim, et al.
Intest Res. 2021;19(1):71-82.

Original Article

Epub September 4, 2020

Management of inflammatory bowel disease in the COVID-19 era
Kyeong Ok Kim, Byung Ik Jang
Intest Res. 2022;20(1):3-10.

Review

Epub February 3, 2021

The role of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio in ulcerative colitis
Yujin Jeong, Seong Ran Jeon, Hyun Gun Kim, et al.
Intest Res. 2021;19(1):62-70.

Original Article

Epub May 8, 2020

Patients with celiac disease are at high risk of developing metabolic syndrome and fatty liver
Ashish Agarwal, Alka Singh, Wajiha Mehtab, et al.
Intest Res. 2021;19(1):106-114.

Original Article

Epub April 22, 2020

Management of Clostridioides difficile infection in patients with inflammatory bowel disease
Sahil Khanna
Intest Res. 2021;19(3):265-274.

Review

Epub August 18, 2020

Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behçet’s disease: results from a large real-world observational study
Yasuo Suzuki, Takashi Hagiwara, Mariko Kobayashi, et al.
Intest Res. 2021;19(3):301-312.

Original Article

Epub August 20, 2020

Natural history of inflammatory bowel disease: a comparison between the East and the West
Eun Mi Song, Suk-Kyun Yang
Intest Res. 2022;20(4):418-430.

Review

Epub December 2, 2021

Quality of life in inflammatory bowel diseases: it is not all about the bowel
Ronald Keller, Nazar Mazurak, Laura Fantasia, et al.
Intest Res. 2021;19(1):45-52.

Original Article

Epub February 27, 2020

Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis
Toshifumi Hibi, Isao Kamae, Philippe Pinton, et al.
Intest Res. 2021;19(1):53-61.

Original Article

Epub April 22, 2020

Temporal trend in the natural history of ulcerative colitis in a country with a low incidence of ulcerative colitis from 2000 through 2018
Satimai Aniwan, Julajak Limsrivilai, Supot Pongprasobchai, et al.
Intest Res. 2021;19(2):186-193.

Original Article

Epub August 18, 2020

Clinical practice guideline for endoscopic resection of early gastrointestinal cancer
Chan Hyuk Park, Dong-Hoon Yang, Jong Wook Kim, et al.
Intest Res. 2021;19(2):127-157.

Statement

Epub October 13, 2020

Pouchitis in inflammatory bowel disease: a review of diagnosis, prognosis, and treatment
Shintaro Akiyama, Victoria Rai, David T. Rubin
Intest Res. 2021;19(1):1-11.

Review

Epub November 5, 2020

An overview of the gut side of the SARS-CoV-2 infection
Bruna Barbosa da Luz, Natalia Mulinari Turin de Oliveira, Isabella Wzorek França dos Santos, et al.
Intest Res. 2021;19(4):379-385.

Review

Epub November 6, 2020

Efficacy and safety of vedolizumab in Crohn’s disease in patients from Asian countries in the GEMINI 2 study
Rupa Banerjee, Sai Wei Chuah, Ida Normiha Hilmi, et al.
Intest Res. 2021;19(1):83-94.

Original Article

Epub December 31, 2020

Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease
Hiroyuki Okamoto, Nathanael L. Dirks, Maria Rosario, et al.
Intest Res. 2021;19(1):95-105.

Original Article

Epub July 10, 2020

Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study
Haruhiko Ogata, Takashi Hagiwara, Takeshi Kawaberi, et al.
Intest Res. 2021;19(4):419-429.

Original Article

Epub November 10, 2020

Efficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI)
Tadakazu Hisamatsu, Hyo Jong Kim, Satoshi Motoya, et al.
Intest Res. 2021;19(4):386-397.

Original Article

Epub December 1, 2020

The role of microbiome in colorectal carcinogenesis and its clinical potential as a target for cancer treatment
Sang Hoon Kim, Yun Jeong Lim
Intest Res. 2022;20(1):31-42.

Review

Epub May 21, 2021

Update on the epidemiology of inflammatory bowel disease in Asia: where are we now?
Sang Hyoung Park
Intest Res. 2022;20(2):159-164.

Review

Epub April 29, 2022

Long-term safety and effectiveness of adalimumab in Japanese patients with Crohn’s disease: 3-year results from a real-world study
Tadakazu Hisamatsu, Yasuo Suzuki, Mariko Kobayashi, et al.
Intest Res. 2021;19(4):408-418.

Original Article

Epub November 20, 2020

Anti-inflammatory diet and inflammatory bowel disease: what clinicians and patients should know?
Nor Hamizah Shafiee, Zahara Abdul Manaf, Norfilza M. Mokhtar, et al.
Intest Res. 2021;19(2):171-185.

Review

Epub February 3, 2021

Prospective validation of CD4+CD25+FOXP3+ T-regulatory cells as an immunological marker to differentiate intestinal tuberculosis from Crohn’s disease
Ritika Rampal, Saurabh Kedia, Mohamad Nahidul Wari, et al.
Intest Res. 2021;19(2):232-238.

Original Article

Epub May 8, 2020

Efficacy and tolerability of exclusive enteral nutrition in adult patients with complicated Crohn’s disease
Sanchit Sharma, Arti Gupta, Saurabh Kedia, et al.
Intest Res. 2021;19(3):291-300.

Original Article

Epub May 26, 2020

Trends of inflammatory bowel disease at a tertiary care center in northern India
Ajit Sood, Kirandeep Kaur, Arshdeep Singh, et al.
Intest Res. 2021;19(3):282-290.

Original Article

Epub August 18, 2020

Yarrow oil ameliorates ulcerative colitis in mice model via regulating the NF-κB and PPAR-γ pathways
Maged E. Mohamed, Sahar A. Elsayed, Hafez R. Madkor, et al.
Intest Res. 2021;19(2):194-205.

Original Article

Epub August 21, 2020

Very early onset inflammatory bowel disease in a South Asian country where inflammatory bowel disease is emerging: a distinct clinical phenotype from later onset disease
Rupa Banerjee, Partha Pal, Zaheer Nabi, et al.
Intest Res. 2021;19(4):398-407.

Original Article

Epub November 20, 2020

  • SCImago Journal & Country Rank
  • AOCC 2018
  • CSIBD
  • JSIBD
  • kasid
  • TSIBD
  • CCF
  • PubMed Central
  • PubMed
  • KoreaMed
  • KoMCI
  • Scopus
  • Directory of Open Access Journals (DOAJ)
  • GoogleScholar
  • EBSCO
  • Similarity Check
  • Crossref Cited-by Linking
  • CrossMark
  • Funder Registry
  • ORCID
  • COPE
  • KOFST
  • TrendMD

ABOUT
ARTICLE & TOPICS
Article Category

Browse all articles >

TOPICS

Browse all articles >

BROWSE ARTICLES
EDITORIAL POLICY
AUTHOR INFORMATION
Editorial Office
Room 310, Lotte Gold Rose II, 31 Seolleung-ro 86-gil, Gangnam-gu, Seoul 06193, Korea
Tel: +82-2-957-6145    Fax: +82-2-957-6146    E-mail: thekasid@irjournal.org                

Copyright © 2023 by Korean Association for the Study of Intestinal Diseases.

Developed in M2PI

Close layer
prev next
Close layer
prev next